Genetic Support for Longevity-Enhancing Drug Targets: Issues, Preliminary Data, and Future Directions

Interventions meant to promote longevity and healthy aging have often been designed or observed to modulate very specific gene or protein targets. If there are naturally occurring genetic variants in such a target that affect longevity as well as the molecular function of that target (eg, the varian...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:The journals of gerontology. Series A, Biological sciences and medical sciences Ročník 74; číslo Suppl_1; s. S61
Hlavní autoři: McCorrison, Jamison, Girke, Thomas, Goetz, Laura H, Miller, Richard A, Schork, Nicholas J
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 13.11.2019
Témata:
Forecasting
Humans
Longevity - drug effects
Longevity - genetics
Preliminary Data
Quantitative Trait Loci
Human Aging
Mortality
Longevity
ISSN:1758-535X, 1758-535X
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Interventions meant to promote longevity and healthy aging have often been designed or observed to modulate very specific gene or protein targets. If there are naturally occurring genetic variants in such a target that affect longevity as well as the molecular function of that target (eg, the variants influence the expression of the target, acting as "expression quantitative trait loci" or "eQTLs"), this could support a causal relationship between the pharmacologic modulation of the target and longevity and thereby validate the target at some level. We considered the gene targets of many pharmacologic interventions hypothesized to enhance human longevity and explored how many variants there are in those targets that affect gene function (eg, as expression quantitative trait loci). We also determined whether variants in genes associated with longevity-related phenotypes affect gene function or are in linkage disequilibrium with variants that do, and whether pharmacologic studies point to compounds exhibiting activity against those genes. Our results are somewhat ambiguous, suggesting that integrating genetic association study results with functional genomic and pharmacologic studies is necessary to shed light on genetically mediated targets for longevity-enhancing drugs. Such integration will require more sophisticated data sets, phenotypic definitions, and bioinformatics approaches to be useful.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1758-535X
1758-535X
DOI:10.1093/gerona/glz206